Review Article | Published:

Staurosporine: new lease of life for parent compound of today’s novel and highly successful anti-cancer drugs

Abstract

Staurosporine, together with such examples as penicillin, aspirin, ivermectin and sildenafil, exemplifies the role that serendipity has in drug discovery and why 'finding things without actually searching for them' retains a prominent role in drug discovery. Hitherto not clinically useful, due to its potency and promiscuity, new delivery technology is opening up new horizons for what was previously just the parent compound of innovative, highly-successful anti-cancer agents.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Ōmura S. Microbial metabolites: 45 years of wandering, wondering and discovering. Tetrahedron. 2011;67:6420–59.

  2. 2.

    Ōmura S. Splendid gifts from microorganisms. Kitasato Institute for Life Sciences. Tokyo: Kitasato University; 2015.

  3. 3.

    Yirga G, Teferi M, Kasaye M. Survey of medicinal plants used to treat human ailments in Hawzen district, Northern Ethiopia. Int J Biodivers Conserv. 2011;3:709–14.

  4. 4.

    Cameron SI, Smith RF, Kierstead KE. Linking medicinal/nutraceutical products research with commercialization. Pharm Biol. 2005;43:425–33.

  5. 5.

    Pan S-Y, et al. New perspectives on how to discover drugs from herbal medicines: CAM’s outstanding contribution to modern therapeutics. Evid Based Complement Altern Med. 2013;2013:627375.

  6. 6.

    Aniszewski T. Alkaloids—secrets of life. 129. Amsterdam: Elsevier; 2007.

  7. 7.

    Sithranga Boopathy N, Kathiresan K. Anticancer drugs from marine flora: an overview. J Oncol. 2010;2010:214186.

  8. 8.

    Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007;70:461–77.

  9. 9.

    Ōmura S, et al. A new alkaloid AM-2282 of Streptomyces origin. Taxonomy, fermentation, isolation and preliminary characterization. J Antibiot. 1977;30:275–82.

  10. 10.

    Sánchez C, Méndez C, Salas JA. Indolocarbazole natural products: occurrence, biosynthesis, and biological activity. Nat Prod Rep. 2006;23:1007–45.

  11. 11.

    Funato N, et al. Absolute configuration of Staurosporine by X-ray analysis. Tetrahedron Lett. 1994;35:1251–4.

  12. 12.

    Schächtele C, Seifert R, Osswald H. Stimulus-dependent inhibition of platelet aggregation by the protein kinase C inhibitors polymyxin B, H-7 and staurosporine. Biochem Biophys Res Commun. 1988;151:542–7.

  13. 13.

    Hachisu M, Hiranuma T, Koyama M, Sezaki M. Antihypertensive compounds with potent protein kinases inhibitory activity. Life Sci. 1989;44:1351–62.

  14. 14.

    Kase H, Iwahashi K, Matsuda Y. K-252a, a potent inhibitor of protein kinase C from microbial origin. J Antibiot. 1986;39:1059–65.

  15. 15.

    Tamaoki T, et al. Staurosporine, a potent inhibitor of phospholipid/Ca++ dependent protein kinase. Biochem Biophys Res Commun. 1986;135:397–402.

  16. 16.

    Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353:172–87.

  17. 17.

    Steeghs N, Nortier JW, Gelderblom H. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann Surg Oncol. 2007;14:942–53.

  18. 18.

    Chen MH, Kerkelä R, Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation. 2008;118:84–95.

  19. 19.

    Karaman MW, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26:127–32.

  20. 20.

    Wender PA, et al. Function through bio-inspired, synthesis-informed design: step economical syntheses of designed kinase inhibitors. Org Chem Front. 2014;1:1166–71.

  21. 21.

    Link JT, et al. Staurosporine and ent-staurosporine: the first total synthesis, prospects for a regioselective approach, and activity profiles. J Am Chem Soc. 1996;118:2825–42.

  22. 22.

    Wood JL, Stoltz BM, Goodman SN. Total synthesis of (+)-RK-286c, (+)-MLR-52, (+)-staurosporine, and (+)-K252a. J Am Chem Soc. 1996;118:10656–7.

  23. 23.

    Johnson LN, Lewis RJ. Structural basis for control by phosphorylation. Chem Rev. 2001;101:2209–42.

  24. 24.

    Adams JA. Kinetic and catalytic mechanisms of protein kinases. Chem Rev. 2001;101:2271–90.

  25. 25.

    Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298:1912–34.

  26. 26.

    Milanesi L, et al. Systematic analysis of human kinase genes: a large number of genes and alternative splicing events result in functional and structural diversity. BMC Bioinform. 2005;6(Suppl 4):S20.

  27. 27.

    Rask-Andersen M, Zhang J, Fabbro D, Schiöth HB. Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014;35:604–20.

  28. 28.

    Huang M, Shen A, Ding J, Geng M. Molecularly targeted cancer therapy: some lessons from the past decade. Trends Pharmacol Sci. 2014;35:41–50.

  29. 29.

    Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin. 2009;59:111–37.

  30. 30.

    Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014;57:5023–38.

  31. 31.

    Barnes PJ. New anti-inflammatory targets for chronic obstructive pulmonary disease. Nat Rev Drug Discov. 2013;12:543–59.

  32. 32.

    Muth F, et al. Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases. J Med Chem. 2015;58:443–56.

  33. 33.

    Kikuchi R, et al. An antiangiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease. Nat Med. 2014;20:1464–71.

  34. 34.

    Banks AS, et al. An ERK/Cdk5 axis controls the diabetogenic actions of PPARγ. Nature. 2015;517:391–5.

  35. 35.

    Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005;315:971–9.

  36. 36.

    Cohen P. Protein kinases—the major drug targets of the twenty-first century? Nat Rev Drug Discov. 2002;1:309–15.

  37. 37.

    Kinch MS. An analysis of FDA-approved drugs for oncology. Drug Discov Today. 2014;19:1831–5.

  38. 38.

    Hantschel O. Unexpected off-targets and paradoxical pathway activation by kinase inhibitors. ACS Chem Biol. 2015;10:234–45.

  39. 39.

    Rix U, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood. 2007;110:4055–63.

  40. 40.

    Druker BJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031–7.

  41. 41.

    Viganò I, et al. First-line treatment of 102 chronic myeloid leukemia patients with imatinib: a long-term single institution analysis. Am J Hematol. 2014;89:E184–E187.

  42. 42.

    Hehlmann R, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol. 2014;32:415–23.

  43. 43.

    Akinaga S, Sugiyama K, Akiyama T. UCN-01 (7-hydroxystaurosporine) and other indolocarbazole compounds: a new generation of anti-cancer agents for the new century? Anticancer Drug Des. 2000;15:43–52.

  44. 44.

    Shabbir M, Stuart R. Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside. Expert Opin Investig Drugs. 2010;19:427–36.

  45. 45.

    Hatzimichael E, Georgiou G, Benetatos L, Briasoulis E. Gene mutations and molecularly targeted therapies in acute myeloid leukemia. Am J Blood Res. 2013;3:29–51.

  46. 46.

    Neul C, et al. Impact of membrane drug transporters on resistance to small-molecule tyrosine kinase inhibitors. Trends Pharmacol Sci. 2016;37:904–32.

  47. 47.

    Fabbro D. 25 years of small molecular weight kinase inhibitors: potentials and limitations. Mol Pharmacol. 2015;87:766–75.

  48. 48.

    Levitzki A. Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. Annu Rev Pharmacol Toxicol. 2013;53:161–85.

  49. 49.

    Davis MI, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011;29:1046–51.

  50. 50.

    Hantschel O, Grebien F, Superti-Furga G. The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL. Cancer Res. 2012;72:4890–5.

  51. 51.

    Garber K. Kinase inhibitors overachieve in CLL. Nat Rev Drug Discov. 2014;13:162–4.

  52. 52.

    Pharma Reports. Kinase inhibitors for treating cancer: Industry analysis, R&D trends and world market forecasts 2014-24. London: Visiongain; 2014.

  53. 53.

    World kinase inhibitors market: Opportunities and forecasts, 2014–22. Portland: Allied Market Research; 2016.

  54. 54.

    Pharma Reports. Kinase Inhibitors for cancer treatment: World industry analysis, R&D and market forecasts 2015-25. London: Visiongain; 2015.

  55. 55.

    Boran AD, Iyengar R. Systems approaches to polypharmacology and drug discovery. Curr Opin Drug Discov Devel. 2010;13:297–309.

  56. 56.

    Reddy AS, Zhang S. Polypharmacology: drug discovery for the future. Expert Rev Clin Pharmacol. 2013;6:41–47.

  57. 57.

    Mukthavaram R, et al. High-efficiency liposomal encapsulation of a tyrosine kinase inhibitor leads to improved in vivo toxicity and tumor response profile. Int J Nanomed. 2013;8:3991–4006.

  58. 58.

    Tang WL, Chen WC, Roy A, Undzys E, Li SD. A simple and improved active loading method to efficiently encapsulate staurosporine into lipid-based nanoparticles for enhanced therapy of multidrug-resistant cancer. Pharm Res. 2016;33:1104–14.

  59. 59.

    Doerig C, Meijer L. Antimalarial drug discovery: targeting protein kinases. Expert Opin Ther Targets. 2007;1:279–90.

  60. 60.

    Fernandez P, et al. The Ser/Thr protein kinase PknB is essential for sustaining mycobacterial growth. J Bacteriol. 2006;188:7778–84.

  61. 61.

    Debrabant A, Lee N, Bertholet S, Duncan R, Nakhasi HL. Programmed cell death in trypanosomatids and other unicellular organisms. Int J Parasitol. 2003;33:257–67.

  62. 62.

    Figarella K, et al. Prostaglandin D2 induces programmed cell death in Trypanosoma brucei bloodstream form. Cell Death Differ. 2005;12:335–46.

  63. 63.

    Figarella K, et al. Prostaglandin-induced programmed cell death in Trypanosoma brucei involves oxidative stress. Cell Death Differ. 2006;13:1802–14.

  64. 64.

    Lee N, et al. Programmed cell death in the unicellular protozoan parasite Leishmania. Cell Death Differ. 2002;9:53–64.

  65. 65.

    Barth T, et al. Staurosporine-induced cell death in Trypanosoma brucei and the role of endonuclease G during apoptosis. Open J Apoptosis. 2014;3:16–31.

  66. 66.

    Doerig C. Protein kinases as targets for anti-parasitic chemotherapy. Biochim Biophys Acta. 2004;1697:155–68.

  67. 67.

    Chow C, Cloutier S, Dumas C, Chou MN, Papadopoulou B. Promastigote to amastigote differentiation of Leishmania is markedly delayed in the absence of PERK eIF2alpha kinase-dependent eIF2alpha phosphorylation. Cell Microbiol. 2011;13:1059–77.

  68. 68.

    Madeira da Silva L, Beverley SM. Expansion of the target of rapamycin (TOR) kinase family and function in Leishmania shows that TOR3 is required for acidocalcisome biogenesis and animal infectivity. Proc Natl Acad Sci USA. 2010;107:11965–70.

  69. 69.

    Dujardin JC, Gonzalez-Pacanowska D, Croft SL, Olesen OF, Spath GF. Collaborative actions in anti-trypanosomatid chemotherapy with partners from disease endemic areas. Trends Parasitol. 2010;26:395–403.

  70. 70.

    Grant KM, et al. Inhibitors of Leishmania mexicana CRK3 cyclin-dependent kinase: chemical library screen and antileishmanial activity. Antimicrob Agents Chemother. 2004;48:3033–42.

  71. 71.

    Zhang Y, et al. Staurosporine shows insecticidal activity against Mythimna separata Walker (Lepidoptera: Noctuidae) potentially via induction of apoptosis. Pestic Biochem Physiol. 2016;128:37–44.

  72. 72.

    Uppuluri, P, Khan A, Edwards JE in Candida albicans: Cellular and Molecular Biology. Current trends in Candidiasis Prasad R editors 5–23 Switzerland: Springer Nature; 2017.

  73. 73.

    LaFayette SL, et al. PKC signalling regulates drug resistance of the fungal pathogen Candida albicans via circuitry comprised of Mkc1, calcineurin, and Hsp90. PLoS Pathog. 2010;6:e1001069.

  74. 74.

    Sohn K, Urban C, Brunner H, Rupp S. EFG1 is a major regulator of cell wall dynamics in Candida albicans as revealed by DNA microarrays. Mol Microbiol. 2003;47:89–102.

  75. 75.

    Shapiro RS, Robbins N, Cowen LE. Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol Mol Biol Rev. 2011;75:213–67.

  76. 76.

    Xie JL, O’Meara TR, Polvi EJ, Robbins N, Cowen LE. Staurosporine induces filamentation in the human fungal pathogen Candida albicans via signalling through Cyr1 and protein kinase A. mSphere. 2017;2:e00056–17.

Download references

Acknowledgements

We would like to thank all fellow researchers and collaborators, too numerous to mention, who have been involved in the discovery, investigation and development of staurosporine and its derivatives.

Author information

Conflict of interest

The authors declare that they have no conflict of interest.

Correspondence to Satoshi Ōmura.

Electronic supplementary material

  1. Supplemental Figure 1

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8